JNJ Stock Risk & Deep Value Analysis
Johnson & Johnson
DVR Score
out of 10
What You Need to Know About JNJ Stock
We analyzed Johnson & Johnson using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran JNJ through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Conservative. Here's what we found.
JNJ Risk Analysis & Red Flags
What Could Go Wrong
The biggest risk for JNJ, despite its broad diversification, remains its exposure to patent expirations and increasing biosimilar competition for blockbuster drugs like Stelara, which generated over $9 billion in annual sales. While JNJ has strategies to mitigate this, any faster-than-expected erosion of this revenue base without sufficient pipeline replenishment or M&A could lead to slower growth, potentially reducing annual revenue by several billion dollars over the next 2-3 years, and impacting investor sentiment.
Risk Matrix
Overall
Conservative
Financial
Low
Market
Low
Competitive
Medium
Execution
Low
Regulatory
Medium
Red Flags
- ⚠
Deceleration of organic revenue growth below 4% for two consecutive quarters, signaling broader market share losses or pipeline weakness.
- ⚠
Significant increase in litigation provisions or adverse judgments exceeding $5 billion in a single quarter, reflecting a material financial impact from ongoing legal challenges (e.g., talc, opioids).
- ⚠
Dividend growth rate significantly slowing or pausing, indicating a fundamental shift in capital allocation priorities or financial stress.
Upcoming Risk Events
- 📅
Q2 2026 Earnings Miss (July 15, 2026): Failure to meet revenue or EPS consensus estimates due to unexpected operational challenges or competitive pressures.
- 📅
Major Patent Expiration (Ongoing/FY2027): Significant revenue decline for a top-selling drug due to unmitigated biosimilar entry (e.g., Stelara biosimilar entry in US in 2025/2026, potential for higher-than-expected erosion).
When to Reconsider
- 🚪
Exit if quarterly revenue drops below $22.5 billion (reflecting ~7% YoY decline from Q1 2026 base).
- 🚪
Sell if net debt-to-EBITDA ratio exceeds 2.0 (currently estimated below 1.5 for JNJ), indicating a deterioration in balance sheet health.
Unlock JNJ Risk Analysis & Red Flags
Create a free account to see the full analysis
Investment Thesis
If Johnson & Johnson continues to deliver consistent mid-single-digit organic revenue growth, driven by key pharmaceutical products and strategic MedTech innovation, while maintaining its strong dividend and capital allocation discipline, then its valuation should remain stable or grow modestly, providing a reliable long-term investment for income and capital preservation. This thesis focuses on stable compounding rather than multi-bagger growth, as the latter is unrealistic for a company of JNJ's scale and maturity.
Is JNJ Stock Undervalued?
Unlock the full AI analysis for JNJ
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
JNJ Price Targets & Strategy
12-Month Target
$245.00
Bull Case
$270.00
Bear Case
$210.00
Valuation Basis
Based on 22.7x forward P/E applied to an estimated FY2026 EPS of $10.80 = $245.
Entry Strategy
Dollar-cost average between $225-$230 (near 50-day SMA). Consider entry on dips towards $215 (strong support zone).
Exit Strategy
Take 50% profit at $245, re-evaluate. Implement a trailing stop-loss at $210 or a 10% decline from peak value.
Portfolio Allocation
2-4% for conservative to moderate risk tolerance, reflecting its stability and income potential rather than growth.
Price Targets & Strategy
Sign up free to unlock price targets and entry/exit strategies
Is JNJ Financially Healthy?
Valuation
P/E Ratio
26.48
Forward P/E
28.41
Profitability
Gross Margin
67.95%
Operating Margin
25.88%
Net Margin
21.83%
Return on Equity
26.26%
Revenue Growth
7.87%
EPS
$8.65
Balance Sheet
Current Ratio
1.03
Quick Ratio
0.69
Debt/Equity
0.59
Cash Flow
Free Cash Flow
$17.00B
Other
Beta (Volatility)
0.26
Dividend Yield
2.32%
Does JNJ Have a Competitive Moat?
Sign in to unlockMoat Rating
🏰 Wide
Moat Trend
Stable
Moat Sources
3 Identified
JNJ's moat is highly durable due to its diversified portfolio across two essential healthcare segments (Pharmaceuticals and MedTech), which provides multiple layers of protection. Its extensive R&D capabilities continuously replenish its drug pipeline and innovative medical devices, while its global scale ensures cost efficiencies and market access.
Moat Erosion Risks
- •Significant patent expirations for blockbuster drugs without adequate pipeline replacement, leading to revenue cliff events.
- •Increased regulatory scrutiny and pricing pressures from governments and payers, impacting drug profitability and market access.
JNJ Competitive Moat Analysis
Sign up to see competitive advantages
JNJ Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral, as JNJ is a mature, defensive stock that typically doesn't attract significant retail social media hype.
Institutional Sentiment
Neutral-Positive, JNJ is a core holding for many institutional investors due to its stability and dividend. No specific analyst upgrades/downgrades were provided in the real-time research, but general sentiment remains stable.
Insider Activity (Form 4)
No Form 4 filings were provided in the search results, so specific insider purchase/sale activity cannot be verified.
Options Flow
Normal options activity, indicating no significant unusual institutional positioning beyond standard hedging or income strategies.
Earnings Intelligence
Next Earnings
2026-07-15 (Q2 2026)
Surprise Probability
Medium, JNJ has a history of slightly beating consensus estimates due to conservative guidance and operational efficiency.
Historical Earnings Pattern
JNJ's stock price typically reacts with modest movements (1-3%) to earnings beats or misses, with larger reactions (up to 5%) often tied to significant guidance changes or major pipeline announcements.
Key Metrics to Watch
Competitive Position
Top Competitor
Eli Lilly (LLY), due to its strong pipeline in high-growth therapeutic areas (diabetes, obesity) and premium valuation driven by innovation.
Market Share Trend
Stable overall, with market share gains in specific innovative pharmaceutical and MedTech sub-segments, offset by some erosion in areas facing biosimilar competition.
Valuation vs Peers
JNJ generally trades at a slight premium to some diversified pharma peers (e.g., Pfizer) but at a discount to high-growth biotechs (e.g., Eli Lilly) on a P/E basis, reflecting its balance of growth and stability.
Competitive Advantages
- •Extensive Intellectual Property and Patent Portfolio across diverse therapeutic areas.
- •Global Distribution and Manufacturing Scale, enabling efficient market penetration.
- •Strong Brand Power and Trust built over decades in consumer and professional healthcare markets.
Market Intelligence
Sign up free to unlock sentiment, earnings intel, and peer analysis
What Could Drive JNJ Stock Higher?
Near-Term (0-6 months)
- •Q2 2026 Earnings Report (July 15, 2026): Positive surprises in pharmaceutical segment growth or MedTech recovery, exceeding current low-single-digit consensus, could drive modest re-rating.
- •Key Pipeline Data Release (Est. Q3 2026): Positive Phase 3 trial results for specific high-potential drug candidates (e.g., targeted oncology, immunology) could add to future revenue visibility.
Medium-Term (6-18 months)
- •Biosimilar Impact Mitigation (FY2027): Successful launch of next-generation drugs or strategic M&A offsetting biosimilar competition for key products like Stelara, maintaining ~3-5% organic revenue growth.
- •MedTech Innovation Cycle (FY2027-FY2028): Acceleration of new product introductions in robotic surgery or orthopedic solutions, driving 5%+ segment-specific revenue growth and market share gains.
Long-Term (18+ months)
- •New Therapeutic Area Expansion (FY2028-FY2029): Entry into novel, high-growth disease areas through significant R&D breakthroughs or strategic large-scale M&A, aiming for an additional $5-10B in annualized revenue.
- •Global Healthcare Market Growth (FY2028-FY2029): Leveraging global scale and distribution to capture incremental market share in emerging markets, contributing to a sustained 4-6% total revenue CAGR.
Catalysts & Growth Drivers
Sign up free to see growth catalysts
What's the Bull Case for JNJ?
- ✓
Watch JNJ's quarterly organic revenue growth rate across segments – sustained growth above 5% indicates strong execution and pipeline success.
- ✓
Monitor the dividend growth rate – a consistent increase of 5%+ annually signals confidence in future cash flows and continued shareholder returns.
Bull Case Analysis
Sign up free to see the bull case
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Johnson & Johnson Makes Money
Johnson & Johnson is a global healthcare giant that develops, manufactures, and sells a broad range of products in two primary segments: Pharmaceuticals and MedTech. It generates revenue by selling prescription medicines for various therapeutic areas (like oncology, immunology, neuroscience) to hospitals and pharmacies, and by providing medical devices and surgical solutions (such as orthopedic products, surgical instruments, and vision care products) to healthcare providers worldwide. Its business model relies on continuous innovation through R&D, patent protection, and extensive global distribution networks to serve both professional medical markets and, historically, consumer health markets (though the consumer division was spun off).
Read Full Business Model BreakdownFAQ
What is the DVR Score for Johnson & Johnson (JNJ)?
As of May 29, 2026, Johnson & Johnson has a DVR Score of 1.0 out of 10, placing it in the "Distressed" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Johnson & Johnson?
Johnson & Johnson's market capitalization is approximately $557.1B..
What is the risk level for JNJ stock?
Our analysis rates Johnson & Johnson's overall risk as Conservative. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of JNJ?
Johnson & Johnson currently has a price-to-earnings (P/E) ratio of 26.5. This is in line with broader market averages.
Does Johnson & Johnson pay a dividend?
Yes, Johnson & Johnson pays a dividend with a current yield of approximately 2.32%.
Is Johnson & Johnson's revenue growing?
Johnson & Johnson has reported revenue growth of 7.9%. The company is growing at a moderate pace.
Is JNJ stock profitable?
Johnson & Johnson has a profit margin of 21.8%. This indicates strong profitability.
How often is the JNJ DVR analysis updated?
Our AI-powered analysis of Johnson & Johnson is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on May 29, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for JNJ (Johnson & Johnson) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.